Company description

Arcturus Therapeutics, Inc. (ARCT) is a biotechnology company that focuses on developing RNA-based therapeutics for the treatment of rare, infectious, and respiratory diseases. Founded in 2013, the company has established itself as a leader in the field of messenger RNA (mRNA) medicine, with a mission to use this emerging technology to transform the way diseases are treated. Arcturus is headquartered in San Diego, California, and has a diverse pipeline of drug candidates in various stages of development. The company's proprietary delivery system, LUNAR, allows for the safe and effective delivery of mRNA therapeutics to target tissues. Arcturus' most advanced drug candidate, ARCT-810, is being developed for the treatment of ornithine transcarbamylase (OTC) deficiency, a rare genetic condition that affects the liver. Other promising candidates in the pipeline include ARCT-032 for cystic fibrosis and ARCT-021 for COVID-19. Arcturus has also entered into strategic partnerships with major pharmaceutical companies like Johnson & Johnson and Ultragenyx to further develop and commercialize its drug candidates. With its innovative approach and strong collaborations, Arcturus is poised to make a significant impact in the field of rare and infectious diseases.